NOFO: Biochemical and Molecular Characterization of Marstacimab and TFPI

Deadline: 01-Jul-2026

The TFPI and Marstacimab Mechanistic Research Grant Program is a competitive funding initiative designed to advance basic scientific understanding of coagulation biology. It supports research on TFPI (Tissue Factor Pathway Inhibitor), marstacimab, and related anti-TFPI monoclonal antibodies. The program aims to strengthen knowledge of molecular and biochemical mechanisms that regulate blood clotting and hemostasis.

Scientific Focus Areas

TFPI Biology and Expression

Research may focus on the molecular structure, biological function, and regulatory role of TFPI in coagulation. Studies may also investigate TFPI isoforms, circulating pools, and tissue-specific expression patterns across different organs.

Marstacimab and Anti-TFPI Mechanisms

Projects may explore how marstacimab and anti-TFPI monoclonal antibodies interact with TFPI at molecular and cellular levels. This includes binding kinetics, biochemical properties, and mechanism-of-action studies.

Coagulation Pathway Interactions

Research may examine TFPI’s role in intrinsic and extrinsic coagulation cascades. Studies may also include interactions with tissue factor and regulatory proteins such as Protein S and Protein C that influence clotting balance.

Pharmacological Interaction Studies

Applicants may investigate how anti-TFPI therapies interact with concomitant medications. This includes pharmacodynamic effects, safety considerations, and combined therapeutic responses.

Advanced Molecular Biology Approaches

The program encourages innovative approaches such as systems biology, molecular assays, and biochemical modeling to improve understanding of coagulation regulation and TFPI-related pathways.

Key Definitions

TFPI is a natural anticoagulant protein that regulates blood clot formation by inhibiting tissue factor–initiated coagulation pathways. Marstacimab is a monoclonal antibody targeting TFPI-related mechanisms to study or modify coagulation processes. Anti-TFPI monoclonal antibodies are engineered biologics designed to bind TFPI and influence clotting regulation.

Funding Details

• Funding per project: up to USD 50,000
• Optional study drug or compound support: up to USD 50,000
• Maximum project duration: 12 months
• Funding type: competitive research grant

Geographic Eligibility

Eligible countries include Brazil, China, Germany, Italy, Japan, Netherlands, Saudi Arabia, South Korea, Spain, Turkey, United Kingdom, and United States.

Who Is Eligible

• Eligible institutions
  • Universities
  • Research organizations
  • Hospitals and clinical research centers
• Principal Investigator (PI) requirements
  • Must hold MD, PhD, or equivalent advanced degree
  • May also hold qualifications in nursing, pharmacy, physiotherapy, or social work
  • Must be affiliated with the applying institution
  • May act through an authorized designee if permitted
• Institutional requirements
  • Only organizations can receive funding (not individuals)
  • Must be legally able to receive funding from the sponsor
  • Multi-institutional collaborations are allowed if each partner has defined roles

Why This Grant Matters

This program strengthens global understanding of coagulation biology and TFPI-related pathways. It supports research that may improve knowledge of blood clot regulation, antibody mechanisms, and pharmacological interactions. The findings may contribute to the development of improved therapeutic strategies for coagulation disorders.

How the Application Process Works

• Confirm eligibility
  • Verify institution is in an eligible country
  • Ensure organization can legally receive funding
• Define research scope
  • Select a TFPI, marstacimab, or coagulation pathway-focused topic
• Prepare proposal
  • Include objectives, methodology, and expected outcomes
  • Provide detailed budget up to USD 50,000
• Confirm institutional participation
  • Ensure all collaborating entities have defined roles
• Submit application
  • Submit through the official grant application system

Common Mistakes to Avoid

• Submitting proposals outside TFPI or coagulation biology scope
• Applying as an individual instead of an eligible institution
• Exceeding the one-year project duration limit
• Missing confirmation of institutional funding eligibility
• Weak mechanistic or biochemical justification
• Lack of clear experimental design or defined outcomes

Tips for a Strong Application

• Focus on clear molecular and biochemical mechanisms
• Provide strong experimental design and measurable endpoints
• Emphasize novelty in coagulation pathway research
• Include interdisciplinary collaboration when relevant
• Align research with pharmacological or translational goals

Frequently Asked Questions

• What is the TFPI and Marstacimab Mechanistic Research Grant Program?
  • It is a competitive funding program supporting foundational research on TFPI biology, marstacimab, and anti-TFPI antibodies
  • It focuses on coagulation mechanisms and molecular biology of blood clot regulation
• Who can apply for this program?
  • Eligible institutions such as:
    • Universities
    • Research organizations
    • Hospitals or clinical research centers
  • Individuals cannot apply directly
  • Principal investigators must be affiliated with an eligible institution
• What is the funding amount and duration?
  • Up to USD 50,000 per project
  • Optional additional support for study drugs or compounds up to USD 50,000
  • Maximum project duration is 12 months
• Which countries are eligible?
  • Brazil
  • China
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Saudi Arabia
  • South Korea
  • Spain
  • Turkey
  • United Kingdom
  • United States
• What research areas are prioritized?
  • TFPI molecular biology and isoforms
  • Marstacimab and anti-TFPI antibody mechanisms
  • Coagulation cascade interactions
  • Pharmacological interaction studies
• Can multiple institutions collaborate?
  • Yes, provided that:
    • Each institution has a defined role
    • The lead organization manages the grant
    • All partners meet eligibility requirements
• What makes a strong application?
  • Clear mechanistic focus on TFPI or coagulation biology
  • Strong experimental design and methodology
  • Well-defined scientific outcomes
  • Relevance to pharmacology or translational research

Conclusion

The TFPI and Marstacimab Mechanistic Research Grant Program supports short-term, high-impact research aimed at advancing understanding of coagulation biology. It enables eligible institutions to explore TFPI pathways and marstacimab mechanisms through focused, well-designed biomedical research projects.

For more information, visit Pfizer.